|
Tenax Therapeutics, Inc. (TENX) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Tenax Therapeutics, Inc. (TENX) Bundle
Unser DCF-Rechner von Tenax Therapeutics, Inc. (TENX) für die Genauigkeit entwickelt, ermöglicht es Ihnen, die Bewertung von Tenax Therapeutics mithilfe aktueller Finanzdaten zu bewerten. Dies bietet vollständige Flexibilität, um alle wesentlichen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -8.3 | -9.7 | -32.4 | -10.9 | -8.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .1 | .1 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -8.4 | -9.8 | -32.5 | -11.0 | -8.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 5.4 | 6.7 | 5.6 | 2.1 | 9.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.7 | .8 | .9 | .4 | 2.1 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -8.4 | -9.9 | -32.7 | -11.0 | -8.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -6.6 | -10.7 | -32.5 | -11.3 | -6.6 | -2.1 | .0 | .0 | .0 | .0 |
| WACC, % | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 | 11.73 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | 7 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | 29.93 |
What You Will Get
- Real Tenax Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Tenax Therapeutics, Inc. (TENX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Tenax Therapeutics, Inc. (TENX).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Tenax Therapeutics, Inc. (TENX)’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Tenax Therapeutics, Inc. (TENX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Tenax Therapeutics, Inc. (TENX).
Key Features
- Comprehensive Data: Tenax Therapeutics' historical financial records and pre-populated projections.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Updates: Observe Tenax Therapeutics' intrinsic value recalculating instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Tenax Therapeutics, Inc.'s (TENX) financial data.
- Customize: Modify forecasts, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare results.
- Make Decisions: Utilize the valuation findings to inform your investment approach.
Why Choose This Calculator for Tenax Therapeutics (TENX)?
- User-Friendly Interface: Perfectly crafted for both novice users and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to tailor your financial analysis.
- Real-Time Valuation: Monitor immediate updates to Tenax’s valuation as you change inputs.
- Preloaded Data: Comes with Tenax’s latest financial information for swift evaluations.
- Favored by Experts: Utilized by analysts and investors for making well-informed investment choices.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about buying or selling Tenax Therapeutics stock (TENX).
- Financial Analysts: Enhance valuation methodologies with easy-to-use financial models tailored for Tenax Therapeutics.
- Consultants: Provide clients with accurate and timely valuation assessments for Tenax Therapeutics.
- Business Owners: Learn how biopharmaceutical companies like Tenax Therapeutics are valued to inform your own business strategies.
- Finance Students: Explore valuation principles using real-time data and case studies related to Tenax Therapeutics.
What the Template Contains
- Pre-Filled Data: Includes Tenax Therapeutics, Inc.'s (TENX) historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for WACC calculations based on customized inputs.
- Key Financial Ratios: Assess Tenax Therapeutics, Inc.'s (TENX) profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.